218 related articles for article (PubMed ID: 31292269)
41. Patterns of bone density evaluation in a community population treated with aromatase inhibitors.
Ligibel JA; O'Malley AJ; Fisher M; Daniel GW; Winer EP; Keating NL
Breast Cancer Res Treat; 2012 Aug; 134(3):1305-13. PubMed ID: 22791365
[TBL] [Abstract][Full Text] [Related]
42. Effects of third-generation aromatase inhibitors on bone.
McCloskey E
Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
[TBL] [Abstract][Full Text] [Related]
43. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
[TBL] [Abstract][Full Text] [Related]
44. Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
Saito T; Ono R; Kono S; Asano M; Fukuta A; Tanaka Y; Takao S; Sakai Y
Breast Cancer Res Treat; 2020 Jul; 182(1):187-193. PubMed ID: 32399742
[TBL] [Abstract][Full Text] [Related]
45. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
46. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
[TBL] [Abstract][Full Text] [Related]
47. Reducing the risk of bone loss associated with breast cancer treatment.
Hadji P
Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
[TBL] [Abstract][Full Text] [Related]
48. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
49. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
[TBL] [Abstract][Full Text] [Related]
50. The diagnostic threshold for osteoporosis impedes fracture prevention in women at high risk for fracture: A registry-based cohort study.
Leslie WD; Seeman E; Morin SN; Lix LM; Majumdar SR
Bone; 2018 Sep; 114():298-303. PubMed ID: 30008396
[TBL] [Abstract][Full Text] [Related]
51. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
[TBL] [Abstract][Full Text] [Related]
52. AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
[TBL] [Abstract][Full Text] [Related]
53. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Spangler L; Yu O; Loggers E; Boudreau DM
J Womens Health (Larchmt); 2013 Feb; 22(2):132-40. PubMed ID: 23362883
[TBL] [Abstract][Full Text] [Related]
54. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
56. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
57. Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.
Mugnier B; Goncalves A; Daumas A; Couderc AL; Mezni E; Viret F; de Nonneville A; Villani P
Osteoporos Int; 2023 Apr; 34(4):703-711. PubMed ID: 36715715
[TBL] [Abstract][Full Text] [Related]
58. The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data.
Abdel-Razeq H; Al-Rasheed U; Mashhadani N; Al-Ibraheem A; Abdel-Razeq R; Jaradeh SA; Mansour R; Bater R; Tbayshat S
Ir J Med Sci; 2022 Dec; 191(6):2511-2515. PubMed ID: 35088228
[TBL] [Abstract][Full Text] [Related]
59. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Sakaguchi K; Ono H; Nakatsukasa K; Ishikawa T; Hasegawa Y; Takahashi M; Niikura N; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Miura D; Yamada K; Yoshimura M; Shioya H; Konishi E; Isao Y; Imai K; Fujikawa K; Taguchi T;
Medicine (Baltimore); 2019 Aug; 98(32):e16770. PubMed ID: 31393399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
